Crism Therapeutics (LSE:CRTX) Total Inventories: £0.00 Mil (As of Dec. 2025)


What is Crism Therapeutics Total Inventories?

Crism Therapeutics LSE:CRTX +10.53% Total Inventories is £0.00 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Crism Therapeutics's total inventories for the quarter that ended in Dec. 2025 was £0.00 Mil. Crism Therapeutics's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was £0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Crism Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was £0.02.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Crism Therapeutics's Days Inventory for the six months ended in Dec. 2025 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Crism Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.00.

Crism Therapeutics  (LSE:CRTX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Crism Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is

Net-Net Working Capital Per Share (Q: Dec. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.128+0.75 * 0.529+0.5 * 0-0.381
-0-0)/51.735
=0.02

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Crism Therapeutics's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=0/0.097*365 / 2
=0.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Crism Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2025 ) / Average Total Inventories (Q: Dec. 2025 )
=0.097 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Crism Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=0 / 0.231
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Crism Therapeutics Total Inventories Related Terms

Crism Therapeutics Total Inventories Historical Data

* Premium members only.

The historical data trend for Crism Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crism Therapeutics Total Inventories Chart

Crism Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Crism Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Crism Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of £0.00 Mil mean?
Crism Therapeutics (LSE:CRTX) has a Total Inventories of £0.00 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Crism Therapeutics and its competitors.
Is Crism Therapeutics' Total Inventories too high?
Crism Therapeutics' current Total Inventories is £0.00 Mil.
How does Crism Therapeutics' Total Inventories compare to VRTX and REGN?
Crism Therapeutics' Total Inventories of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Crism Therapeutics and its competitors. Crism Therapeutics's current Total Inventories is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (LSE:CRTX) has a current Total Inventories of £0.00 Mil. The current Total Inventories is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Crism Therapeutics (LSE:CRTX), the current Total Inventories is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crism Therapeutics Business Description

Address Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.